Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134

Molecular Oncology

Volumn 8, Issue 5, 2014, Pages 956-967

  Hashim, Yassar M ^a   Spitzer, Dirk ^a,b   Vangveravong, Suwanna ^a   Hornick, Mary C ^a   Garg, Gunjal ^a   Hornick, John R ^a   Goedegebuure, Peter ^a,b   Mach, Robert H ^a,c   Hawkins, William G ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

IAPs; Pancreas cancer; Selective delivery; Sigma 2 receptor; Smac

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIGMA 2 OPIATE RECEPTOR; SW IV 134; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AZABICYCLO DERIVATIVE; CASPASE 3; OLIGOPEPTIDE; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR; SW IV-134; SIGMA 1 OPIATE RECEPTOR; SW 43;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; MURINE MODEL; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UNITED STATES; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; APOPTOSIS; CANCER CELL LINE; DRUG PROTEIN BINDING; DRUG TARGETING; PANCREAS CANCER; SURVIVAL;

INTRACISTERNAL A-PARTICLES; MURINAE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; AZABICYCLO COMPOUNDS; CASPASE 3; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PANCREAS; PANCREATIC NEOPLASMS; RECEPTORS, SIGMA;

EID: 84903549599     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.03.005     Document Type: Article

References (42)

1. American Cancer Society Cancer Facts & Figures 2010 2010, American Cancer Society, Atlanta.
2. Arlt A., Muerkoster S.S., Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer lett. 2013, 332:346-358.
3. Besmer D.M., Curry J.M., Roy L.D., Tinder T.L., Sahraei M., Schettini J., Hwang S.I., Lee Y.Y., Gendler S.J., Mukherjee P. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer res. 2011, 71:4432-4442.
4. Dehdashti F., Laforest R., Gao F., Shoghi K.I., Aft R.L., Nussenbaum B., Kreisel F.H., Bartlett N.L., Cashen A., Wagner-Johnston N., Mach R.H. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J. Nucl. Med. Official Publ. Soc. Nucl. Med. 2013, 54:350-357.
5. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999, 13:239-252.
6. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
7. Dineen S.P., Roland C.L., Greer R., Carbon J.G., Toombs J.E., Gupta P., Bardeesy N., Sun H., Williams N., Minna J.D., Brekken R.A. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer res. 2010, 70:2852-2861.
8. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
9. Hornick J.R., Vangveravong S., Spitzer D., Abate C., Berardi F., Goedegebuure P., Mach R.H., Hawkins W.G. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J. Exp. Clin. cancer Res.: CR 2012, 31:41.
10. Hornick J.R., Xu J., Vangveravong S., Tu Z., Mitchem J.B., Spitzer D., Goedegebuure P., Mach R.H., Hawkins W.G. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol. cancer 2010, 9:298.
11. Huang S., Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer res. 2008, 68:2944-2951.
12. Kashiwagi H., McDunn J.E., Simon P.O., Goedegebuure P.S., Vangveravong S., Chang K., Hotchkiss R.S., Mach R.H., Hawkins W.G. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J. Translational Med. 2009, 7:24.
13. Kashiwagi H., McDunn J.E., Simon P.O., Goedegebuure P.S., Xu J., Jones L., Chang K., Johnston F., Trinkaus K., Hotchkiss R.S., Mach R.H., Hawkins W.G. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol. cancer 2007, 6:48.
14. Komar G., Kauhanen S., Liukko K., Seppanen M., Kajander S., Ovaska J., Nuutila P., Minn H. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin. cancer Res. Official J. Am. Assoc. Cancer Res. 2009, 15:5511-5517.
15. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science N. Y. 2004, 305:1471-1474.
16. Mach R.H., Smith C.R., al-Nabulsi I., Whirrett B.R., Childers S.R., Wheeler K.T. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997, 57:156-161.
17. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197:517-532.
18. Oeckinghaus A., Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harbor Perspect. Biol. 2009, 1:a000034.
19. Ogawa K., Shiba K., Akhter N., Yoshimoto M., Washiyama K., Kinuya S., Kawai K., Mori H. Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy. Cancer Sci. 2009, 100:2188-2192.
20. Oost T.K., Sun C., Armstrong R.C., Al-Assaad A.S., Betz S.F., Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T., Oleksijew A., Oltersdorf T., Rosenberg S.H., Shoemaker A.R., Tomaselli K.J., Zou H., Fesik S.W. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 2004, 47:4417-4426.
21. Ostenfeld M.S., Fehrenbacher N., Hoyer-Hansen M., Thomsen C., Farkas T., Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer res. 2005, 65:8975-8983.
22. Peng Y., Sun H., Nikolovska-Coleska Z., Qiu S., Yang C.Y., Lu J., Cai Q., Yi H., Kang S., Yang D., Wang S. Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. J. Med. Chem. 2008, 51:8158-8162.
23. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., Taylor D.P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13:85-86.
24. Rothe M., Pan M.G., Henzel W.J., Ayres T.M., Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83:1243-1252.
25. Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M., Alnemri E.S., Fairman R., Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 2003, 11:519-527.
26. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clinic. 2012, 62:10-29.
27. Spitzer D., Simon P.O., Kashiwagi H., Xu J., Zeng C., Vangveravong S., Zhou D., Chang K., McDunn J.E., Hornick J.R., Goedegebuure P., Hotchkiss R.S., Mach R.H., Hawkins W.G. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res. 2012, 72:201-209.
28. Su T.P. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit. Rev. Neurobiol. 1993, 7:187-203.
29. Sun H., Nikolovska-Coleska Z., Yang C.Y., Qian D., Lu J., Qiu S., Bai L., Peng Y., Cai Q., Wang S. Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc. Chem. Res. 2008, 41:1264-1277.
30. Sun H., Stuckey J.A., Nikolovska-Coleska Z., Qin D., Meagher J.L., Qiu S., Lu J., Yang C.Y., Saito N.G., Wang S. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J. Med. Chem. 2008, 51:7169-7180.
31. Tinder T.L., Subramani D.B., Basu G.D., Bradley J.M., Schettini J., Million A., Skaar T., Mukherjee P. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J. Immunol. Baltimore, Md. 1950 2008, 181:3116-3125.
32. Vangveravong S., Xu J., Zeng C., Mach R.H. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg. Med. Chem. 2006, 14:6988-6997.
33. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., Flygare J.A., Fairbrother W.J., Deshayes K., Dixit V.M., Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
34. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
35. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., Brink R., Leverkus M., Tergaonkar V., Schneider P., Callus B.A., Koentgen F., Vaux D.L., Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
36. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., Rice K.C. Sigma receptors: biology and function. Pharmacol. Rev. 1990, 42:355-402.
37. Wei Z., Mousseau D.D., Dai Y., Cao X., Li X.M. Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS. Pharmacogen. J. 2006, 6:279-288.
38. Wu H., Tschopp J., Lin S.C. Smac mimetics and TNFalpha: a dangerous liaison?. Cell 2007, 131:655-658.
39. Xu J., Zeng C., Chu W., Pan F., Rothfuss J.M., Zhang F., Tu Z., Zhou D., Zeng D., Vangveravong S., Johnston F., Spitzer D., Chang K.C., Hotchkiss R.S., Hawkins W.G., Wheeler K.T., Mach R.H. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nature Commun. 2011, 2:380.
40. Zeng C., Vangveravong S., McDunn J.E., Hawkins W.G., Mach R.H. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer. Br. J. Cancer 2013.
41. Zeng C., Vangveravong S., Xu J., Chang K.C., Hotchkiss R.S., Wheeler K.T., Shen D., Zhuang Z.P., Kung H.F., Mach R.H. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res. 2007, 67:6708-6716.
42. Zobel K., Wang L., Varfolomeev E., Franklin M.C., Elliott L.O., Wallweber H.J., Okawa D.C., Flygare J.A., Vucic D., Fairbrother W.J., Deshayes K. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 2006, 1:525-533.